Takumi Harada

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Tatsuaki Sumiyoshi · 5 shared papers, 2023–2026 · strength 1.11
   • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
   • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
2. Kenjiro Okada · 5 shared papers, 2023–2026 · strength 1.11
   • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
   • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
3. Ryuta Shintakuya · 5 shared papers, 2023–2026 · strength 1.11
   • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
   • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
4. Kenichiro Uemura · 5 shared papers, 2023–2026 · strength 1.11
   • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
   • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
5. Yoshiaki Murakami · 4 shared papers, 2024–2026 · strength 0.91
   • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
   • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
6. Shin’ya Takahashi · 4 shared papers, 2023–2025 · strength 0.84
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
   • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
   • Paper Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. DOI 10.1245/s10434-024-15221-z↗
7. Yasutaka Ishii · 3 shared papers, 2024–2026 · strength 0.70
   • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
   • Paper Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. DOI 10.1245/s10434-024-15221-z↗
8. Kenta Baba · 3 shared papers, 2024–2025 · strength 0.65
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
   • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
   • Paper Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. DOI 10.1245/s10434-024-15221-z↗
9. Shiro Oka · 2 shared papers, 2025–2026 · strength 0.51
   • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
   • Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
10. Shinya Takahashi · 1 shared paper, 2026 · strength 0.26
    • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
11. Sho Tazuma · 1 shared paper, 2026 · strength 0.26
    • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
12. Juri Ikemoto · 1 shared paper, 2026 · strength 0.26
    • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
13. Masaru Furukawa · 1 shared paper, 2026 · strength 0.26
    • Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
14. Takeshi Sudo · 1 shared paper, 2024 · strength 0.21
    • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
15. Naru Kondo · 1 shared paper, 2024 · strength 0.21
    • Paper Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer … DOI 10.1002/jhbp.1412↗
16. Shinya Nakamura · 1 shared paper, 2024 · strength 0.20
    • Paper Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. DOI 10.1245/s10434-024-15221-z↗
17. Eiso Hiyama · 1 shared paper, 2023 · strength 0.19
    • Paper Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2023.10.019↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.